Buyers on the lookout for high-yield dividend shares to purchase now ought to flip their consideration towards the healthcare sector: Three comparatively dependable drugmakers are buying and selling close to their 52-week lows.Their inventory costs could have been crushed down, but it surely’s greater than doubtless that higher days are forward. Here is how these shares might produce heaps of passive earnings for affected person buyers who purchase now.1. PfizerShares of Pfizer (NYSE: PFE) have fallen about 55% from their early 2022 peak. At latest costs, they provide an eye-popping 6.2% dividend yield. In a nutshell, the inventory tanked as a result of gross sales of its COVID-related merchandise fell a lot sooner than anticipated.Earnings-seeking buyers can be glad to know that Pfizer is aware of the best way to handle by way of intervals when gross sales of some of its medication are quickly declining. The pharmaceutical large has been capable of increase its dividend payout yearly since 2009, and this is not the primary time a few of its largest income streams have all of a sudden dried up.Regardless of declining gross sales of its COVID-19 merchandise, administration expects adjusted earnings of between $2.15 per share and $2.35 per share this yr. That can be greater than sufficient to cowl a dividend payout at the moment set at $1.68 per share yearly.Buyers can fairly count on one other 15 years of regular payout raises from Pfizer. The Meals and Drug Administration accredited a report 9 new medication for the corporate in 2023, and people aren’t even its solely new sources of income. In 2023, Pfizer acquired Seagen, a most cancers drug developer with 4 commercialized therapies.2. Johnson & JohnsonJohnson & Johnson (NYSE: JNJ) inventory is down about 22% from the all-time excessive it touched in 2021. In April, the drug and medical know-how firm raised its dividend payout for the 62nd yr in a row.J&J additionally skilled COVID-19 product gross sales that fell as shortly as they rose, however that did not stop it from elevating its dividend payout by 30.5% over the previous 5 years. At latest costs, shares of Johnson & Johnson supply a pleasant 3.4% yield.Shareholders can look ahead to extra vital payout bumps. Final yr, Johnson & Johnson accomplished the spin-off of its comparatively slow-growing shopper items phase into a brand new firm named Kenvue. This yr, administration expects adjusted earnings per share to rise by 7.7% on the midpoint of its steering vary.Loads might occur over the subsequent 62 years, however buyers can fairly count on no less than one other decade of great dividend development from J&J as its numerous companies thrive. For instance, within the first quarter, gross sales of the corporate’s Impella coronary heart pumps soared 15% yr over yr, and there are no competing gadgets on the horizon.Story continuesMedical know-how is not the one working phase that is firing on all cylinders for J&J nowadays. Factoring out the impression of COVID-19 vaccine gross sales, its pharmaceutical income rose 8.3% yr over yr within the first quarter.3. Bristol Myers SquibbShares of Bristol Myers Squibb (NYSE: BMY) have dropped by about 50% from the height they reached in late 2022. At its beaten-down value, the pharma inventory presents a 5.9% dividend yield.In December, Bristol Myers Squibb raised its quarterly payout for the fifteenth consecutive yr, and people payout bumps have been extra sturdy than these supplied by most of its friends. The pharmaceutical firm has raised its payouts by 46% over the previous 5 years.The inventory market has been hammering Bristol Myers Squib inventory partly as a result of it reported a heavy lack of $11.9 billion within the first quarter. That loss was attributable to a $12.9 billion cost it recorded for acquired in-process analysis and growth (IPR&D) — in different phrases, points associated to latest acquisitions. Within the first quarter alone, it accomplished transactions with 4 corporations, together with Karuna Therapeutics.Karuna is growing a next-generation schizophrenia therapy referred to as KarXT that has already been proven in medical research to considerably enhance signs. The Meals and Drug Administration is reviewing it now, and its choice is predicted to be introduced on or earlier than Sept. 26.Bristol Myers Squibb generated $12.5 billion in free money movement over the previous yr and wanted simply 38% of this sum to cowl its dividend funds. With potential assist from KarXT and a handful of different just lately acquired candidates in late-stage growth, one other 15-year streak of dividend raises is not an unreasonable expectation.Do you have to make investments $1,000 in Pfizer proper now?Before you purchase inventory in Pfizer, take into account this:The Motley Idiot Inventory Advisor analyst workforce simply recognized what they imagine are the 10 finest shares for buyers to purchase now… and Pfizer wasn’t one in all them. The ten shares that made the minimize might produce monster returns within the coming years.Think about when Nvidia made this listing on April 15, 2005… should you invested $1,000 on the time of our advice, you’d have $801,365!*Inventory Advisor gives buyers with an easy-to-follow blueprint for achievement, together with steering on constructing a portfolio, common updates from analysts, and two new inventory picks every month. The Inventory Advisor service has greater than quadrupled the return of S&P 500 since 2002*.See the ten shares »*Inventory Advisor returns as of June 10, 2024Cory Renauer has no place in any of the shares talked about. The Motley Idiot has positions in and recommends Bristol Myers Squibb, Kenvue, and Pfizer. The Motley Idiot recommends Johnson & Johnson and recommends the next choices: lengthy January 2026 $13 calls on Kenvue. The Motley Idiot has a disclosure coverage.3 Excessive-Yield Dividend Shares Close to Their 52-Week Lows to Purchase and Maintain was initially revealed by The Motley Idiot